15 April 2014 - Deborah Wilkes
Archived
Johnson & Johnson said "strong sales" of Zyrtec, including initial stocking of the new Dissolve Tabs line extension, had helped push up its OTC sales in the US by 3.4% to US$366 million in the first quarter of 2014.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.